Wird geladen...
Delafloxacin: design, development and potential place in therapy
Delafloxacin (DLX) is a new fluoroquinolone pending approval, which has shown a good in vitro and in vivo activity against major pathogens associated with skin and soft tissue infections and community-acquired respiratory tract infections. DLX also shows good activity against a broad spectrum of mic...
Gespeichert in:
| Veröffentlicht in: | Drug Des Devel Ther |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove Medical Press
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5367733/ https://ncbi.nlm.nih.gov/pubmed/28356714 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S106071 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|